Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 6/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | GRB2 | P62993 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29468902 | 0.92 | GRB2 (0.47) | CAPN1CTSBGRB2OPRM1OPRD1 | |
| SCHEMBL19492652 | 0.85 | CAPN1 (0.62) | CAPN1CTSBGRB2OPRM1OPRD1 | |
| SCHEMBL30852867 | 0.84 | CAPN1 (0.41) | CAPN1CTSBGRB2OPRM1 | |
| SCHEMBL30543482 | 0.82 | GRB2 (0.52) | GRB2OPRM1 | |
| SCHEMBL31501249 | 0.81 | APLNR (0.41) | CAPN1CTSBGRB2OPRM1OPRD1 | |
| SCHEMBL30543490 | 0.80 | CMA1 (0.42) | CAPN1CTSBGRB2XIAP | |
| SCHEMBL30455247 | 0.78 | CAPN1 (0.52) | CAPN1CTSBGRB2OPRM1OPRD1 | |
| SCHEMBL29396765 | 0.78 | CAPN1 (0.52) | CAPN1CTSBGRB2OPRM1OPRD1 | |
| SCHEMBL17229184 | 0.76 | CAPN1 (0.62) | CAPN1CTSBGRB2OPRM1 | |
| SCHEMBL16488741 | 0.76 | CAPN1 (0.62) | CAPN1CTSBGRB2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125423-A1 | PEPTIDES FOR INCRETIN SYNTHESIS | LILLY CO ELI (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4598938-A2 | PEPTIDES FOR INCRETIN SYNTHESIS | Eli Lilly and Company (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024077149-A2 | PEPTIDES FOR INCRETIN SYNTHESIS | ELI LILLY AND COMPANY (US) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125423-A1 | PEPTIDES FOR INCRETIN SYNTHESIS | IAPP, GLP1R, VIP | CAPN1 3223/4885CTSB 756/4885GRB2 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.